Zepatier

Zepatier is very well tolerated with minimal side effects. In clinical trials, very few people—around 1%—discontinued treatment due to side effects. The most commonly reported side effects are fatigue and headaches. These side effects are considered mild and are comparable in patients with or without cirrhosis. Nausea, insomnia, and diarrhea have also been reported. Zepatier has not been studied in people who are pregnant or nursing, so its impact on fetal development or nursing babies is unknown.

Before starting Zepatier, be sure to tell your medical provider or pharmacist about all of the medications, supplements, and herbal products you take, whether they are prescribed, over-the-counter, or recreational. It is important to report any changes to your medications as they happen during treatment. Zepatier should not be taken with HIV medications that require a booster (meaning they require another medication such as ritonavir or cobicistat to increase the drug levels in the body), such as atazanavir, darunavir, or elvitegravir. Zepatier should also not be taken with the HIV medications efavirenz or etravirine. Use with certain statins (cholesterol medicine) may cause increased risk of muscle pain (myopathy) or muscle breakdown (rhabdomyolysis). Your doctor should determine if your statin may be continued or changed during treatment with Zepatier. There are no interactions with methadone or other common medications used for opioid, alcohol, or nicotine dependency. Unlike several of the other HCV medications, Zepatier does not interact with acid reducing agents. It should not be taken with rifamycin antimicrobials such as rifabutin, rifampin, or rifapentine, nor should it be taken with the anticonvulsants carbamazepine, phenytoin, phenobarbital, or oxcarbazepine. It cannot be taken with St. John’s wort; in general, herbal products should be avoided due to lack of information regarding potential for interaction.

Zepatier was an excellent medication when it was released, but it is no longer used as much as the other newer treatments are preferred due to potential need for an additional lab test and limited genotypes (only 1 and 4) covered. If you have HCV genotype 1a, you will need to get an HCV drug resistance blood test before starting Zepatier. If your hepatitis C virus is resistant, you should be prescribed an alternate regimen. It is an excellent regimen for patients with kidney disease, including those on hemodialysis, with 99% achieving a cure. NS3/4A protease inhibitors, such as grazoprevir, are contraindicated (cannot be taken) in people with moderate or severe liver impairment (Child-Pugh B/C), which is also called decompensated cirrhosis. Using Zepatier in decompensated cirrhosis may cause significantly higher amounts of grazoprevir in the blood and may increase ALT (a liver enzyme).

For more information, GO TO hcvguidelines.org.

Black Box Warning

Before starting treatment with any direct-acting antiviral (DAA), including Zepatier, patients should take a blood test to check for hepatitis B (HBV) infection. HBV infection could worsen or reactivate during or after DAA treatment, potentially leading to serious liver problems, including liver failure or death. Patients with current or past HBV infection should be monitored during HCV DAA treatment, and some may need to take HBV treatment. SEE HBV Reactivation for more information and consult your medical provider.